The White House claims prescription drug prices posted their largest annual decline in more than 60 years, attributing the drop to its Most Favored Nation pricing policy, under which 17 drugmakers covering roughly 86% of the branded market agreed to align U.S. prices with those of other developed nations.
The release credits its TrumpRx platform with generating $700 million in savings and cites GLP-1 drugs falling from over $1,000 to as low as $149 a month, alongside cuts of 50–90% on fertility drugs, inhalers, insulin, and cholesterol treatments.
The statement declares President Trump the first president to actually lower drug prices, a superlative offered without independent verification, competing data sources, or any accounting of what these companies gained in return.
The full dispatch is available from the source below.